跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Abbott Laboratories GmbH

首页临床试验发起方与机构Abbott Laboratories GmbH

Abbott Laboratories GmbH

ACTIVE

Justus-von-Liebig-Str. 33, Neustadt Am Rübenberge, Niedersachsen, 德国abbott.deSubsidiary

隶属于雅培

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

15

15 进行中

药物批准

20

批准总数

监管机构

4

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

6

40.0%

3 期

1

6.7%

Phase 3 4

1

6.7%

试验状态分布

进行中（未招募）

15

100.0%

相关临床试验

该机构主办的试验（15）

A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone versus Crinone intravaginal progesterone gel for Luteal Support in In-Vitro Fertilization (LOTUS II)

进行中（未招募）

Jan 20161066 名受试者

A randomized multicentre study comparing the effectiveness, safety and tolerance of daily oral dygesterone against Crinone gel for use in in-vitro fertilization (IVF)

进行中（未招募）

May 20151066 名受试者

A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects with Pancreatic Exocrine Insufficiency due to Cystic Fibrosis

进行中（未招募）

Dec 201478 名受试者

A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects with Pancreatic Exocrine Insufficiency due to Cystic Fibrosis

进行中（未招募）

Dec 201470 名受试者

A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects with Pancreatic Exocrine Insufficiency due to Cystic Fibrosis

进行中（未招募）

Nov 201478 名受试者

A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects with Pancreatic Exocrine Insufficiency due to Cystic Fibrosis

进行中（未招募）

Nov 201478 名受试者

A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.

进行中（未招募）

Dec 20131066 名受试者

A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.

进行中（未招募）

Dec 20131066 名受试者

第 1 页，共 2 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

3

药物批准

FDA

Food and Drug Administration

1

药物批准

PHILIPPINES

Philippines FDA

1

药物批准

SFDA

Saudi Food and Drug Authority

15

药物批准

近期批准

CEFAJECT 500 mg IM

VALIP 2 mg film-coated tablets

CEFAJECT 1 g IV

VALIP 4 mg film-coated tablets

CEFAJECT 1 g IM

PHYSIOTENS 0.2 MG F.C TAB

PHYSIOTENS O.4 MG F.C.TAB

资讯

暂无资讯文章

本页目录

概览
相关临床试验15
药物批准20
资讯

返回机构列表